Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Lacosamide
Drug ID BADD_D01238
Description Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. Recent studies indicate that Lacosamide only affects those neurons which are depolarized or active for long periods of time, typical of neurons at the focus of an epileptic seizure, as opposed to other antiepileptic drugs such as carbamazepine or lamotrigine which slow the recovery from inactivation and reduce the ability of neurons to fire action potentials.
Indications and Usage Lacosamide is indicated for adjunctive therapy for partial onset seizures in patients with epilepsy over 17 years old. Injection is indicated for short term use when oral therapy is not feasible.
Marketing Status approved
ATC Code N03AX18
DrugBank ID DB06218
KEGG ID D07299
MeSH ID D000078334
PubChem ID 219078
TTD Drug ID D05OFX
NDC Product Code 73289-0063; 73289-0064; 14445-012; 66651-914; 16714-549; 27808-246; 0131-5410; 47335-918; 50228-193; 51407-721; 51991-348; 51991-349; 60687-698; 65162-923; 65162-926; 68083-480; 68462-680; 69539-026; 72865-235; 36998-1810; 0904-7244; 65977-0075; 14445-132; 31722-627; 31722-814; 31722-815; 0131-2479; 42291-862; 47335-980; 53746-925; 66689-108; 69543-455; 70710-1886; 0904-7246; 0904-7247; 65372-1186; 0131-2478; 47335-922; 53746-926; 60687-676; 65862-749; 66689-109; 67877-736; 68462-678; 68462-681; 62332-173; 65862-747; 12828-0087; 14445-021; 42765-060; 65862-720; 68225-057; 14445-129; 14445-130; 31722-813; 60505-0405; 62332-171; 65219-204; 65862-748; 69367-350; 72603-140; 13612-0021; 0904-7245; 50370-0024; 66039-882; 27808-244; 31722-812; 0131-1810; 46708-171; 47335-943; 50228-192; 62332-172; 62332-174; 69367-348; 70771-1682; 36998-2478; 16714-552; 27808-245; 0131-2480; 42291-860; 42934-303; 46708-172; 46708-173; 51407-722; 51991-351; 60687-687; 67877-733; 67877-735; 69367-351; 69539-025; 70954-488; 36998-0119; 36998-2480; 52038-005; 53747-069; 62331-062; 16714-548; 25021-791; 31722-203; 0121-1012; 0121-2024; 46708-174; 51991-350; 65162-924; 65162-925; 66689-107; 67877-734; 69539-027; 72205-220; 72266-242; 16436-0101; 17180-2746; 36998-2477; 36998-2479; 16714-550; 53746-924; 65862-750; 66689-110; 69539-028; 73289-0065; 17205-107; 0131-2477; 42291-861; 42291-863; 50228-194; 51407-723; 51407-724; 53746-923; 68462-679; 69367-349; 70710-1359; 14445-131; 14445-406; 27808-243; 50228-195
UNII 563KS2PQY5
Synonyms Lacosamide | Vimpat | N-benzyl-2-acetamido-3-methoxypropionamide | N benzyl 2 acetamido 3 methoxypropionamide | N-benzyl-AcMeOPrNH2 | N benzyl AcMeOPrNH2
Chemical Information
Molecular Formula C13H18N2O3
CAS Registry Number 175481-36-4
SMILES CC(=O)NC(COC)C(=O)NCC1=CC=CC=C1
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neonatal respiratory distress syndrome18.04.10.003; 22.11.02.0100.001463%Not Available
Panniculitis lobular23.07.02.0050.001463%Not Available
Persecutory delusion19.10.01.0070.001463%Not Available
Pulmonary artery stenosis24.04.09.011; 22.06.03.0060.001463%Not Available
Toxic optic neuropathy17.04.05.009; 12.03.01.033; 06.02.08.0030.002194%Not Available
Hypothermia neonatal18.04.06.004; 12.05.03.002; 08.05.01.0070.001463%Not Available
Breast cancer metastatic21.05.01.016; 16.10.01.0080.001463%Not Available
Cell death14.11.02.005; 08.03.03.0030.001463%Not Available
Sopor19.02.04.002; 17.02.04.0210.003657%Not Available
Psychogenic seizure17.12.03.042; 19.24.01.0070.003949%Not Available
Sputum retention22.02.03.0120.001463%Not Available
Stress cardiomyopathy24.04.04.026; 02.04.01.0120.002194%Not Available
Encephalitis autoimmune17.06.05.002; 16.32.01.006; 10.04.10.0120.001463%Not Available
Change in seizure presentation17.12.03.0220.002194%Not Available
Disorganised speech19.19.02.005; 17.02.08.0170.001463%Not Available
Tongue discomfort07.14.02.0190.003218%Not Available
Behaviour disorder19.01.01.0050.010385%Not Available
Drug effective for unapproved indication08.06.01.037; 12.09.02.0010.004973%Not Available
Drug ineffective for unapproved indication12.09.02.002; 08.06.01.0380.016820%Not Available
Focal dyscognitive seizures17.12.02.0050.004680%Not Available
Hepatic cytolysis09.01.07.0360.002194%Not Available
Immobilisation syndrome15.03.05.017; 08.01.03.0920.001463%Not Available
Intermenstrual bleeding21.01.01.0150.005704%Not Available
Juvenile myoclonic epilepsy17.12.03.0370.001463%Not Available
Neonatal cardiac failure18.04.07.013; 02.05.01.0150.001463%Not Available
Skin laceration23.03.11.041; 12.01.06.016--Not Available
Suspected suicide19.12.01.009; 08.04.01.0170.001463%Not Available
Therapeutic product ineffective08.06.01.0570.001463%Not Available
Therapeutic response changed08.06.01.0590.002194%Not Available
Treatment noncompliance12.09.02.006; 08.06.01.0670.016674%Not Available
The 10th Page    First    Pre   10    Total 10 Pages